Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
NETSTREIT Corp. (NTST)
KE Holdings Inc. (BEKE)
RedBall Acquisition Corp. (RBAC.U)
Upcoming IPO
Vistas Media Acquisition (VMACU)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
NavSight Holdings (NSH.U)
dMY Technology Group II (DMYD.U)
Duck Creek Technologies, Inc. (DCT)
CureVac B.V. (CVAC)
Dragoneer Growth Opportunities (DGNR.U)
Northern Genesis Acquisition (NGA.U)
Inhibrx, Inc. (INBX)
Harmony Biosciences Holdings, Inc. (HRMY)
Priced IPO
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
More companies

Zentalis Pharmaceuticals, LLC (ZNTL)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. They use their highly efficient drug discovery engine, which they refer to as their Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that they believe could result in potentially differentiated product profiles. Their discovery engine combines their extensive experience and capabilities across cancer biology and medicinal chemistry. They believe their product candidates are differentiated from current programs targeting similar pathways and, if approved, have the potential to significantly impact clinical outcomes of patients with cancer.
Industry
PHARMACEUTICAL PREPARATIONS
CEO CFO
Anthony Y. Sun Melissa B. Epperly
Employees Founded
62 2014

Contacts

Address: 530 Seventh Avenue, Suite 2201, New York, NY 10018, US

Telephone: (212) 433-3791

Web page: http://www.zentalis.com

IPO information

Expected Date 4/3/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $558.8
Revenues (MM) $0
Net Income (Loss) (MM) $-45.7

Voting

What do you think will happen with the ZNTL share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 7.65
Shares Revised (MM) 9.2
Expected offer amount (MM) $165.2
Realized offer amount(MM) $165.6
Underwriters
Morgan Stanley/ Jefferies/ SVB Leerink/ Guggenheim Securities
CO-Managers
-

Sector: Healthcare

Tweets about $ZNTL

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats